Comparison of Systemic and Mucosal Synchronous Immunization with Replicating Single-cycle Adenoviruses and SOSIP Protein HIV-1 Vaccines

Most infections with the human immunodeficiency virus begin at the body's soft, wet entry points: the lining of the vagina, the rectum, the mouth, or the nose. At these mucosal surfaces, the battle against the virus starts with a tiny number of invaders, sometimes just a single particle. If a vaccine could stop the virus right there, at the very moment it tries to cross the barrier, it might prevent the infection from ever taking hold. For decades, scientists have tried to build vaccines that work this way, but the standard method of injection—shooting a needle deep into a muscle—often fails to create a strong enough shield at these specific entry points. While muscle injections send immune signals throughout the body, they do not always teach the immune system how to guard the mucosal gates effectively. This leaves a critical gap in protection, prompting researchers to ask a simple but difficult question: does it matter where you put the vaccine?

A team of scientists at the Mayo Clinic and other institutions set out to answer this by testing a new strategy in rhesus macaques, a type of monkey often used to study human diseases. They wanted to see if delivering a vaccine directly to the site where the virus enters the body would offer better protection than the standard muscle shot. To do this, they used two different types of vaccine components. The first was a protein that mimics the outer shell of the virus, designed to train the immune system to recognize the enemy. The second was a unique, gene-based tool: a modified adenovirus, which is a common cold virus, that had been engineered to act as a delivery truck. This truck carries the genetic instructions for the virus's outer shell into the body's cells. Crucially, this truck was designed to replicate its cargo many times inside the cell to make a huge amount of the viral protein, but it was disabled so it could not spread to other cells or cause an actual infection. This "single-cycle" design allowed the vaccine to generate a massive immune response without the safety risks of a fully replicating virus.

The researchers divided the monkeys into groups and gave them the same combination of these two vaccine parts, but they changed the route of delivery for the gene-based truck. One group received the truck by a standard injection into the arm muscle. Another group received it as a liquid spray up the nose. The third group received it by injection directly into the vaginal wall, the very place where the virus would later try to enter. All groups received the protein component by muscle injection, as that was the only method known to work for that specific protein at the time. The monkeys were vaccinated four times over several months, with the researchers carefully shielding the viral trucks with a protective coating each time to ensure the immune system would recognize them as new targets rather than dismissing them as old friends.

After the vaccination series was complete, the researchers waited a long time—more than a year and a half—to see if the protection would last. Then, they began a rigorous test. They exposed the monkeys to the virus through the vagina once a week for ten weeks. This repeated challenge mimicked real-world scenarios where a person might be exposed to the virus multiple times. The results were striking. Every monkey in the control group and every monkey that received the vaccine through the arm muscle became infected within the first ten exposures. The monkeys that received the spray up the nose fared no better; most of them became infected quickly as well. However, the group that received the gene-based vaccine directly into the vaginal wall told a different story. Half of these monkeys resisted all ten attempts to infect them. Even among those that did eventually catch the virus, the viral levels in their blood were lower than in the other groups.

The study suggests that the location of the vaccine matters more than the type of vaccine itself. While the muscle-injected monkeys developed strong immune signals in their blood, those signals were not enough to stop the virus at the vaginal door. The monkeys that received the vaccine directly at the site of infection built a localized defense that was far more effective at blocking the virus. This finding challenges the assumption that a strong immune response in the blood is sufficient for protection against sexually transmitted infections. It indicates that to stop the virus at the gate, the immune system may need to be trained right at the gate itself. The researchers noted that while this direct injection method worked well in the study, it is not a practical solution for humans, as injecting a vaccine into the vaginal wall is not a feasible routine for the general population. The real value of the discovery lies in proving that mucosal barriers can be fortified, suggesting that future vaccines must find new ways to deliver their message to the specific tissues where the virus strikes, rather than relying solely on the standard muscle shot.